Dr. Hung founded Nuvation Bio in 2018 and serves as President and Chief Executive Officer and member of the Board of Directors. Dr. Hung founded Medivation, Inc., in 2003, raising a total of $433 million in public offerings over the life of the company. In 2016, Medivation was sold to Pfizer for $14.3 billion in an all-cash deal. Dr. Hung identified, in-licensed and led the development of enzalutamide (XTANDI®) for advanced prostate cancer. XTANDI, approved in 60+ countries, reached blockbuster drug status, reaching nearly $6 billion in global annual sales in 2023. At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, which was approved by the FDA in October 2018. Prior to Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a medical device that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. Dr. Hung currently serves as Chairman of the Board of Directors of T-Therapeutics and as a member of the Board of Directors of Novocure. He received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine.